Save with our new Non-Invasive Prenatal Package! This great value package includes our Non-Invasive Prenatal Paternity DNA Test as well as our Prenatal Peace Genetic Screening AND our NEW Baby Gender Screening! All for one low price.

Our ‘Prenatal Peace’ or ‘NIFTY™’ (Non-Invasive Fetal Trisomy test) is a safe, simple, non-invasive prenatal testwhich offers screening for certain genetic conditions from as early as week 10 of pregnancy.Using the latest genetic sequencing technology, NIFTY™ has over >99% accuracy for the three most common trisomy conditions present at birth, which are Down Syndrome, Edwards Syndrome and Patau Syndrome.

Are you having a baby boy or baby girl? Are you curious to find out? With a 98% accuracy rate, our baby gender DNA test using a simple Maternal blood sample will give you the definite answer you need as early as 10 weeks of Pregnancy. The test we offer has been extensively validated and endorsed and no other baby gender test offers such accurate results so early in your pregnancy.

Postnatal Peace” or “Nova™” is a genetic screening test (Newborn – 5 years) that determines a baby’s risk for 50 inherited disorders, as well as providing personalised genetic information on the metabolism of 20 drugs. Nova™ utilises Next Generation sequencing technology, coupled with the leading genetics bioinformatics software. Postnatal peace is able to offer the most comprehensive and accurate newborn screening test that is over 99.99% accurate.

Our Inherited Disease Panel tests over 300 genes applicable to over 700 unique inherited diseases, including neuromuscular, cardiovascular, developmental, and metabolic diseases. This screening test can be used for preconception testing of prospective parents to screen for potential overlapping genetic disorders as well as diagnosis of inherited conditions.

Pharmacogenomics (PGx) is the analysis of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. PGx can provide information about a patient’s genetic likelihood to respond to a given medication or risk of an adverse drug response (ADR).

Cystic fibrosis is a condition which mainly affects the lungs and pancreas, but can affect other parts of the body, including the liver, nose and sinuses, reproductive organs, and sweat glands. Our Cystic Fibrosis testing is performed using massive parallel sequencing (next generation sequencing) which allows for the analysis of exons, intron-exon boundaries, and UTRs that contain common mutations in the CFTR gene. This methodology with sequence analysis of all exons, intron/ exon borders, promoter regions, and specific intronic regions detects more than 98% of CFTR mutations.

This Specialized Test Panel includes screening of BRCA1 and BRCA2 genes. Mutations in BRCA1 and BRCA2 increase the risk of developing female breast and ovarian cancers as well as other cancers including pancreatic cancer and endometrial cancer.

An allergy is a response of the immune system where the body’s defense can react to a harmless substance such as pollen, food and even drugs. Almost anything can trigger an allergic reaction, which can range from mild and sometimes it can be life-threatening. We are pleased to now be offering New Clinical Diagnostic Solutions for Allergy and Autoimmune Testing.

Establish your genetic risk of hereditary cancers. We offer a cancer panel test which will look for a total of 92 mutations associated with hereditary cancers. The genetic predisposition test for cancer is a powerful tool that can help you reduce your risks or undertake measures that will help you detect any cancers as early as possible.

Genetic Testing is now available for ctDNA in blood. DNA is extracted from plasma and highly sensitive testing is then used to detect specific DNA mutations in the circulating cell-free tumour DNA enabling early detection of cancer, monitoring of disease progression and response to treatment.

Targeted Sequencing Panel covering 50 genes involved in cancer. This panel is ideal for ovarian cancer, breast cancer, prostate cancer and bladder cancer, providing analysis of genes that may offer suitable drug targets.

Over 70 fusion transcripts associated with lung cancer.

Targeted Sequencing Panel covering 22 genes involved in lung cancer, bowel cancer, melanoma and pancreatic cancer. For lung cancer, we are also able to test for RNA fusions including ALK, RET, ROS-1 and NTRK-1.

Targeted Sequencing Panel covering 19 genes involved in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).

Several other molecular pathology tests are under development. For information about specific requirements please contact the laboratory. Medicare rebates may be available on some tests.

This site uses cookies. Find out more about this site’s cookies.